Completion pneumonectomy is safe and effective in select patients with recurrent non-small cell lung cancer.
Lung cancer
perioperative complications
surgical technique
Journal
Journal of thoracic disease
ISSN: 2072-1439
Titre abrégé: J Thorac Dis
Pays: China
ID NLM: 101533916
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
entrez:
11
4
2020
pubmed:
11
4
2020
medline:
11
4
2020
Statut:
ppublish
Résumé
Locoregional recurrence rates for non-small cell lung cancer (NSCLC) remain high, even following curative surgical resection. While national guidelines advocate surgical resection for locoregional recurrence, it is rarely offered when resection would require completion pneumonectomy, which available literature associates with a 12-36% perioperative mortality and 40-80% morbidity. Additionally, survival advantages to radical surgery in this scenario are largely unknown, particularly because available series often include patients undergoing completion pneumonectomy for benign indications or metastatic disease from other primary sites, making extrapolation to primary lung cancer patients challenging. As systemic therapy options continue to evolve, particularly as it relates to immunotherapy, we expect that there will be more and more opportunities for locoregional surgical control. The aim of this study was to evaluate outcomes following completion pneumonectomy for recurrent NSCLC. We retrospectively reviewed all patients who underwent completion pneumonectomy for recurrent NSCLC at our institution between 2000 and 2015. Factors affecting perioperative morbidity and mortality, as well as overall survival, were analyzed. Between 2000 and 2015, 28 patients underwent completion pneumonectomy for recurrent lung cancer (14 female, 14 male). The median age was 64.2 years (range, 36.7-84.0). There were 11 left-sided and 17 right-sided operations. Fourteen patients (50.0%) underwent chemotherapy or chemoradiotherapy prior to surgery. Perioperative morbidity was seen in 13 of 28 (46.4%) patients, and atrial fibrillation was the most common complication. Mortality at 30- and 90-day intervals was 3.6%, and 14.3% respectively. Five-year overall survival was 43.1% and was not associated with preoperative chemotherapy or chemoradiotherapy use. Patients over 70 years old (n=5) experienced a statistically higher rate of postoperative complications (100.0% Completion pneumonectomy is a viable treatment option for patients with recurrent NSCLC. We attribute our low risks of major morbidity, such as bronchopleural fistula, to careful patient selection and technique. In patients over 70 years, morbidity is higher which should inform discussion regarding surgical options.
Sections du résumé
BACKGROUND
BACKGROUND
Locoregional recurrence rates for non-small cell lung cancer (NSCLC) remain high, even following curative surgical resection. While national guidelines advocate surgical resection for locoregional recurrence, it is rarely offered when resection would require completion pneumonectomy, which available literature associates with a 12-36% perioperative mortality and 40-80% morbidity. Additionally, survival advantages to radical surgery in this scenario are largely unknown, particularly because available series often include patients undergoing completion pneumonectomy for benign indications or metastatic disease from other primary sites, making extrapolation to primary lung cancer patients challenging. As systemic therapy options continue to evolve, particularly as it relates to immunotherapy, we expect that there will be more and more opportunities for locoregional surgical control. The aim of this study was to evaluate outcomes following completion pneumonectomy for recurrent NSCLC.
METHODS
METHODS
We retrospectively reviewed all patients who underwent completion pneumonectomy for recurrent NSCLC at our institution between 2000 and 2015. Factors affecting perioperative morbidity and mortality, as well as overall survival, were analyzed.
RESULTS
RESULTS
Between 2000 and 2015, 28 patients underwent completion pneumonectomy for recurrent lung cancer (14 female, 14 male). The median age was 64.2 years (range, 36.7-84.0). There were 11 left-sided and 17 right-sided operations. Fourteen patients (50.0%) underwent chemotherapy or chemoradiotherapy prior to surgery. Perioperative morbidity was seen in 13 of 28 (46.4%) patients, and atrial fibrillation was the most common complication. Mortality at 30- and 90-day intervals was 3.6%, and 14.3% respectively. Five-year overall survival was 43.1% and was not associated with preoperative chemotherapy or chemoradiotherapy use. Patients over 70 years old (n=5) experienced a statistically higher rate of postoperative complications (100.0%
CONCLUSIONS
CONCLUSIONS
Completion pneumonectomy is a viable treatment option for patients with recurrent NSCLC. We attribute our low risks of major morbidity, such as bronchopleural fistula, to careful patient selection and technique. In patients over 70 years, morbidity is higher which should inform discussion regarding surgical options.
Identifiants
pubmed: 32274087
doi: 10.21037/jtd.2020.01.51
pii: jtd-12-03-217
pmc: PMC7139098
doi:
Types de publication
Journal Article
Langues
eng
Pagination
217-222Informations de copyright
2020 Journal of Thoracic Disease. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: The authors have no conflicts of interest to declare.
Références
Eur J Cardiothorac Surg. 2012 Sep;42(3):405-9
pubmed: 22398467
Ann Thorac Surg. 2008 Dec;86(6):2008-16; discussion 2016-8
pubmed: 19022040
Thorax. 2006 Jul;61(7):597-603
pubmed: 16449262
Ann Thorac Surg. 2002 Sep;74(3):876-83; discussion 883-4
pubmed: 12238854
J Thorac Oncol. 2012 Oct;7(10):1556-62
pubmed: 22982656
Kardiochir Torakochirurgia Pol. 2015 Mar;12(1):18-25
pubmed: 26336473
Transl Lung Cancer Res. 2014 Aug;3(4):242-9
pubmed: 25806307
Eur J Cardiothorac Surg. 2013 Jul;44(1):e53-8
pubmed: 23557919
Ann Thorac Surg. 2013 Jun;95(6):1885-90; discussion 1890-1
pubmed: 23647859
J Thorac Cardiovasc Surg. 1993 May;105(5):918-24
pubmed: 8487570
Chest. 2000 Apr;117(4 Suppl 1):104S-109S
pubmed: 10777463
J Thorac Cardiovasc Surg. 2001 Mar;121(3):484-90
pubmed: 11241083